
TY  - JOUR
TI  - Satellite Symposium
JO  - Pain Practice
VL  - 7
IS  - s1
SN  - 1530-7085
UR  - https://doi.org/10.1111/j.1533-2500.2007.00136_2.x
DO  - doi:10.1111/j.1533-2500.2007.00136_2.x
SP  - 4
EP  - 4
PY  - 2007
ER  - 

TY  - JOUR
AU  - Stocchi, Luca
AU  - Nelson, Heidi
TI  - Laparoscopic colectomy for colon cancer: Trial update
JO  - Journal of Surgical Oncology
JA  - J. Surg. Oncol.
VL  - 68
IS  - 4
SN  - 0022-4790
UR  - https://doi.org/10.1002/(SICI)1096-9098(199808)68:4<255::AID-JSO10>3.0.CO;2-Z
DO  - doi:10.1002/(SICI)1096-9098(199808)68:4<255::AID-JSO10>3.0.CO;2-Z
SP  - 255
EP  - 267
KW  - laparoscopy
KW  - colorectal neoplasm
KW  - length of hospital stay
KW  - surgical complications
KW  - learning curve
PY  - 1998
AB  - Abstract Laparoscopic colon surgery is gaining acceptance for benign conditions, but cannot yet be considered an established procedure for malignancy. The main reported benefit of the technique is the reduction in length of hospital stay. Other potential benefits such as cosmesis, improvement in quality of life, physiologic and immunologic advantages, as well as reduced complication rates have not been clearly demonstrated. Concerns about laparoscopic colon surgery for cancer including the possibility of inadequate resection, tumor staging, and altered tumor spread due to pneumoperitoneum have only been partially addressed by retrospective and experimental studies and require a prospective randomized trial for definitive resolution. Details of the trial currently underway sponsored by the National Institutes of Health are described. Although innovations in clinical practice and increased familiarity account for the expanding popularity of laparoscopic colon surgery, results from this and similar worldwide trials are needed before this approach can be recommended for cancer. J. Surg. Oncol. 68:255?267, 1998. ? 1998 Wiley-Liss, Inc.
ER  - 

TY  - JOUR
TI  - e-Posters
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 101
IS  - s2
SN  - 0007-1323
UR  - https://doi.org/10.1002/bjs.9475
DO  - doi:10.1002/bjs.9475
SP  - 7
EP  - 14
PY  - 2014
ER  - 

TY  - JOUR
TI  - Poster Sessions
JO  - Tropical Medicine & International Health
JA  - Trop Med Int Health
VL  - 22
IS  - S1
SN  - 1360-2276
UR  - https://doi.org/10.1111/tmi.12979
DO  - doi:10.1111/tmi.12979
SP  - 115
EP  - 345
PY  - 2017
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - Haemophilia
JA  - Haemophilia
VL  - 24
IS  - S1
SN  - 1351-8216
UR  - https://doi.org/10.1111/hae.13393
DO  - doi:10.1111/hae.13393
SP  - 32
EP  - 135
PY  - 2018
ER  - 

C7  - pp. 245-253
TI  - Staphylococci
SN  - 9780632064175
UR  - https://doi.org/10.1002/9780470757253.ch24
DO  - doi:10.1002/9780470757253.ch24
SP  - 245-253
KW  - staphylococci
KW  - micrococcaceae
KW  - staphylococcus aureus
KW  - staphylococcus epidermidis
KW  - staphylococcus saprophyticus
PY  - 2018
AB  - Summary This chapter contains sections titled: Classification
ER  - 

TY  - JOUR
AU  - Bassetti, D.
AU  - Bassetti, M.
AU  - Tillotson, G.
AU  - Watson, S.
TI  - Abstracts of the 2nd International Meeting on Antimicrobial Chemotherapy in Clinical Practice, Portofino, Italy, October 21–24, 2001
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
VL  - 21
IS  - 11P3
SN  - 9780632064175
UR  - https://doi.org/10.1592/phco.21.19.331S.34435
DO  - doi:10.1592/phco.21.19.331S.34435
SP  - 331S
EP  - 388S
PY  - 2001
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - British Journal of Haematology
JA  - Br J Haematol
VL  - 169
IS  - s1
SN  - 9780632064175
UR  - https://doi.org/10.1111/bjh.13350
DO  - doi:10.1111/bjh.13350
SP  - 1
EP  - 104
PY  - 2015
ER  - 

TY  - JOUR
TI  - Hemodialysis Abstracts from the 36th Annual Dialysis Conference February 27–March 1, 2016 Seattle, Washington
JO  - Hemodialysis International
JA  - Hemodial Int
VL  - 20
IS  - 1
SN  - 9780632064175
UR  - https://doi.org/10.1111/hdi.12392
DO  - doi:10.1111/hdi.12392
SP  - 134
EP  - 183
PY  - 2016
ER  - 

TY  - JOUR
TI  - Contributed Poster Presentations
JO  - Value in Health
VL  - 8
IS  - 6
SN  - 9780632064175
UR  - https://doi.org/10.1111/j.1524-4733.2005.00063.x
DO  - doi:10.1111/j.1524-4733.2005.00063.x
SP  - A23
EP  - A220
PY  - 2005
ER  - 

TY  - JOUR
TI  - Poster Presentation – Respiratory Infections (Non-Tuberculosis)
JO  - Respirology
JA  - Respirology
VL  - 19
IS  - S3
SN  - 9780632064175
UR  - https://doi.org/10.1111/resp.12417_14
DO  - doi:10.1111/resp.12417_14
SP  - 208
EP  - 227
PY  - 2014
ER  - 

TY  - JOUR
TI  - Bristol Cup Posters: Summaries of Posters
JO  - British Journal of Dermatology
VL  - 155
IS  - s1
SN  - 9780632064175
UR  - https://doi.org/10.1111/j.1365-2133.2006.07253.x
DO  - doi:10.1111/j.1365-2133.2006.07253.x
SP  - 21
EP  - 61
PY  - 2006
ER  - 

TY  - JOUR
TI  - Abstracts for papers selected for presentation at the Combined Meeting of the British Society for Haematology and the British Society for Haemostasis and Thrombosis, Glasgow, 20–22 March 1991
JO  - British Journal of Haematology
VL  - 77
IS  - s1
SN  - 9780632064175
UR  - https://doi.org/10.1111/j.1365-2141.1991.tb07997.x
DO  - doi:10.1111/j.1365-2141.1991.tb07997.x
SP  - 1
EP  - 84
PY  - 1991
ER  - 

TY  - JOUR
TI  - 2013 ASPHO abstracts
JO  - Pediatric Blood & Cancer
JA  - Pediatr. Blood Cancer
VL  - 60
IS  - S2
SN  - 9780632064175
UR  - https://doi.org/10.1002/pbc.24509
DO  - doi:10.1002/pbc.24509
SP  - S1
EP  - S105
PY  - 2013
ER  - 

TY  - JOUR
AU  - North, Richard
AU  - Shipley, Jane
TI  - Practice Parameters for the Use of Spinal Cord Stimulation in the Treatment of Chronic Neuropathic Pain
JO  - Pain Medicine
VL  - 8
IS  - s4
SN  - 9780632064175
UR  - https://doi.org/10.1111/j.1526-4637.2007.00388.x
DO  - doi:10.1111/j.1526-4637.2007.00388.x
SP  - S200
EP  - S275
KW  - Spinal Cord Stimulation
KW  - Neuropathic Pain
KW  - Indications
KW  - Patient Selection
KW  - Outcomes
KW  - Prognostic Factors
KW  - Risk Management
KW  - Device Options
KW  - Patient Management
KW  - Delivery of Health Care
KW  - Quality of Health Care
KW  - Cost-Effectiveness
PY  - 2007
AB  - ABSTRACT Introduction.? Physicians, policy makers, and other interested parties require a synthesized, critical, and clear compilation of the following information to optimize spinal cord stimulation (SCS) for neuropathic pain: 1) indications and potential beneficial outcomes; 2) answers to key clinical questions; 3) cost/resource use implications; and 4) the quality and source of the evidence. This information must be nonjudgmental and noncoercive and have the sole objective of increasing the reader's expertise. Study Design.? Evidence-based literature review and consensus statement. Methods.? We consulted with experts to identify clinical-practice questions. Then, we conducted a critical literature review (MEDLINE, EMBASE, 1967 through March 2007) to grade treatment practices from ?options? to ?recommended.? We created a bibliographical database of all citations pertinent to each practice question. Several experts not otherwise involved reviewed the draft document. Results.? We answered 64 questions covering 1) indications; 2) potential beneficial outcomes; 3) prognostic factors; 4) patient selection for screening trial; 5) procedural risk management; 6) screening trial; 7) device options; 8) patient management; 9) factors affecting the delivery and quality of SCS treatment; and 10) cost-effectiveness. Most of our more than 300 references are cited multiple times (in each pertinent category). This is the first overview that seeks to categorize and place the entire SCS clinical literature at the disposal of the reader. It presents the first grading system that incorporates, among other evidence sources, an assessment of the likelihood of a favorable outcome based on the evidence provided by expert consensus combined with consideration of the risk and potential benefit of an action. Conclusions.? The Practice Parameters for Spinal Cord Stimulation in the Treatment of Neuropathic Pain answers important questions. It assesses supporting evidence and provides specific citations to enable the reader to conduct further study. The document will be updated regularly in a Web-based version.
ER  - 

TY  - JOUR
TI  - Abstracts: International Society for Developmental Psychobiology
JO  - Developmental Psychobiology
JA  - Dev. Psychobiol.
VL  - 53
IS  - 7
SN  - 9780632064175
UR  - https://doi.org/10.1002/dev.20603
DO  - doi:10.1002/dev.20603
SP  - 738
EP  - 770
PY  - 2011
ER  - 

TY  - JOUR
TI  - Poster Session
JO  - Pediatric Pulmonology
JA  - Pediatr Pulmonol
VL  - 54
IS  - S2
SN  - 9780632064175
UR  - https://doi.org/10.1002/ppul.22495
DO  - doi:10.1002/ppul.22495
SP  - S155
EP  - S480
PY  - 2019
ER  - 

TY  - JOUR
TI  - PUBLICATION
JO  - Hematological Oncology
JA  - Hematol Oncol
VL  - 31
IS  - S1
SN  - 9780632064175
UR  - https://doi.org/10.1002/hon.2059
DO  - doi:10.1002/hon.2059
SP  - 201
EP  - 270
PY  - 2013
ER  - 

TY  - JOUR
TI  - Abstracts of the IPOS 11th World Congress of Psycho-Oncology
JO  - Psycho-Oncology
JA  - Psycho‐Oncology
VL  - 18
IS  - S2
SN  - 9780632064175
UR  - https://doi.org/10.1002/pon.1594
DO  - doi:10.1002/pon.1594
SP  - S1
EP  - S340
PY  - 2009
ER  - 

TY  - JOUR
AU  - Purroy, F.
AU  - Suárez-Luis, I.
AU  - Cambray, S.
AU  - Farré, J.
AU  - Benabdelhak, I.
AU  - Mauri-Capdevila, G.
AU  - Sanahuja, J.
AU  - Quílez, A.
AU  - Begué, R.
AU  - Gil, M. I.
AU  - Molina-Seguin, J.
AU  - Torreguitart, N.
TI  - The determination of copeptin levels helps management decisions among transient ischaemic attack patients
JO  - Acta Neurologica Scandinavica
JA  - Acta Neurol Scand
VL  - 134
IS  - 2
SN  - 9780632064175
UR  - https://doi.org/10.1111/ane.12523
DO  - doi:10.1111/ane.12523
SP  - 140
EP  - 147
KW  - biomarker
KW  - transient ischaemic attack
KW  - copeptin
KW  - prognosis
PY  - 2016
AB  - Background Most approaches to transient ischaemic attack (TIA) triage use clinical scores and vascular imaging; however, some biomarkers have been suggested to improve the prognosis of TIA patients. Methods Serum levels of copeptin, adiponectin, neopterin, neuron-specific enolase, high-sensitivity C-reactive protein, IL-6, N-terminal pro-B-type natriuretic peptide, S100?, tumour necrosis factor-alpha and IL-1α as well as clinical characteristics were assessed on consecutive TIA patients during the first 24 h of the onset of symptoms. Results Among 237 consecutive TIA patients, 12 patients (5%) had a stroke within 7 days and 15 (6%) within 90 days. Among all candidate biomarkers analysed, only copeptin was significantly increased in patients with stroke recurrence (SR) within 7 days (P = 0.026) but not within 90 days. A cut-off point of 13.8 pmol/l was established with a great predictive negative value (97.4%). Large artery atherosclerosis (LAA) [hazard ratio (HR) 12.7, 95% CI 3.2?50.1, P < 0.001] and copeptin levels ≥13.8 pmol/l (HR 3.9, 95% CI 1.01?14.4, P = 0.039) were independent predictors of SR at the 7-day follow-up. LAA was the only predictor of 90-day SR (HR 7.4, 95% CI 2.5?21.6, P < 0.001). ABCD3I was associated with 7- and 90-day SRs (P = 0.025 and P = 0.034, respectively). The association between copeptin levels and LAA had a diagnostic accuracy of 90.3%. Conclusions Serum copeptin could be an important prognostic biomarker to guide management decisions among TIA patients. Therefore, TIA patients with copeptin levels below 13.8 pmol/l and without LAA have an insignificant risk of 7-day SR and could be managed on an outpatient basis.
ER  - 
